TX-KINAXIS
5.3.2024 13:01:37 CET | Business Wire | Press release
Kinaxis® Inc. (TSX: KXS), the leading supply chain management platform, today announced collaborations with two prominent non-profit organizations – Women Who Code and Ellen MacArthur Foundation – to accelerate the company’s vision to preserve the planet’s resources and enrich the human experience. The partnerships were announced within the company’s new 2023 Sustainability Report which highlights the latest environmental, social, and governance (ESG) metrics to coincide with annual financial reporting and disclosures.
Kinaxis will work with Women Who Code, whose mission is to empower diverse women to excel in technology careers and the Ellen MacArthur Foundation, which advocates for the creation of a circular economy to eliminate waste and pollution, circulate products and materials, and regenerate nature.
Both organizations are focused on supporting and elevating innovators and changemakers to solve some of the world’s most pressing problems, which mirrors how Kinaxis is approaching solving the complexities of supply chain.
“Both Women Who Code and the Ellen MacArthur Foundation are committed to creating a world where the only limiting factor is your own imagination. We couldn’t be more thrilled to explore ways we can work with them as supply chain resiliency and sustainability take on new levels of importance in our new era of never-ending disruptions,” said John Sicard, president and chief executive officer at Kinaxis. “Our ambition to power the world’s supply chains is a big one and we know we can’t do it all on our own which is why collaborations with likeminded organizations are so critical to helping us advance a circular economy and socially responsible future for all.”
Women Who Code provides engineers, developers, data scientists, architects, designers and other technologists with the tools, resources, and opportunities they need to grow and succeed in their tech related careers. In keeping with the company’s commitment to shaping a more inclusive and equitable future for women in tech, Kinaxis will engage with the organization by ramping up membership recruitment efforts, establishing a new mentorship program and providing resources that spark interest in supply chain careers.
By becoming a Member of the Ellen MacArthur Foundation’s Network, Kinaxis will collaborate with the organization’s extensive network of circular economy leaders and practitioners to advance circular practices in the industry and get involved with groundbreaking research projects designed to drive innovation at scale. Moving away from a ‘take, make, waste’ linear model, the circular economy offers businesses the opportunity to redesign their supply chains to meet these needs, as well as reduce costs and cut greenhouse gas emissions.
Sicard continues: “As the single largest consumer of the Earth’s natural resources – whether it’s the materials used to make something, the resources required to store something, or the emissions expelled to ship something – supply chains are poised to make a significant positive impact, not just because regulations demand it.”
With more than 40,000 users in 100+ countries, Kinaxis works with some of the world’s biggest brands in sectors such as CPG, automotive, high tech, life sciences and more. Its AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end-to-end from strategic planning to last-mile delivery. Kinaxis technology helps companies that supply the agricultural industry with 40% of the world’s tractors, helps keep more than 110,000,000,000 teeth clean each year, and ensures more than 35 million pets are fed nutritious meals each year.
More details on the new partnerships and the company’s corporate giving program can be found in the 2023 Sustainability Report.
To learn more about Kinaxis and its supply chain management solutions, please visit Kinaxis.com.
About Kinaxis
Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305961661/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom